Fig. 3
From: The discovery of biological subphenotypes in ARDS: a novel approach to targeted medicine?
Class assignment to subphenotypes of ARDS, associated 90-day mortality and mortality according to different treatment. ARMA acute respiratory management of acute lung injury, ALVEOLI assessment of low tidal volume and elevated end-expiratory volume to obviate lung injury, MARS molecular diagnosis and risk stratification of sepsis, FACTT fluid and catheter treatment trial, SAILS statins for acutely injured lungs from sepsis, HARP hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in acute lung injury to reduce pulmonary dysfunction, PEEP positive end-expiratory pressure, P2 hyperinflammatory subphenotype, P1 hypoinflammatory subphenotype